.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Practice

The Top 5 Biosimilars Articles for the Week of August 21

August 25th 2017

By The Center for Biosimilars Staff

Article

The Center for Biosimilars recaps the top 5 stories in biosimilars news for the week of August 21, 2017.

Auto-Injector for Biosimilar Etanercept Equivalent in Dosing, Tolerability to Pre-Filled Syringe

August 23rd 2017

By Kelly Davio

Article

A study published in the British Journal of Clinical Pharmacology demonstrated the bioequivalence of GP2015, a biosimilar etanercept treatment (Sandoz’s Erelzi), when delivered with an auto-injector and when delivered with pre-filled syringe in patients across a variety of body weights.

Practice

The Top 5 Biosimilars Articles for the Week of August 21

Auto-Injector for Biosimilar Etanercept Equivalent in Dosing, Tolerability to Pre-Filled Syringe

Biosimilars in the Next 5 Years

State Legislation on Biosimilars and Substitution

Naming and Coding of Biosimilars

Cost, Patient Programs, and Access to Biosimilars

Competition and Cost for Biosimilars

Cost and Biosimilars in Oncology

Extrapolation of Indications in Biosimilars

Payer Intervention and Biosimilar Switching